Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Preclinical Development: Overview01:28

Preclinical Development: Overview

6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

13.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.5K
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems01:22

Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems

333
Bioavailability is a critical pharmacological concept that measures the extent and rate at which an active drug ingredient or therapeutic moiety enters the systemic circulation, remaining unchanged. It's a pivotal factor in determining a drug's efficacy and safety.The Biopharmaceutics Classification System (BCS) plays an essential role in drug development by categorizing drugs into four classes based on their solubility and permeability. This classification aids in understanding drug absorption...
333
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

94
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

2.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
2.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Exploring the prognostic impact of absolute lymphocyte count in patients treated with immune-checkpoint inhibitors.

BJC reports·2024
Same author

Patient and Public Involvement to Optimise a Patient Information Leaflet Format.

Irish medical journal·2024
Same author

Management of newly diagnosed glioblastoma multiforme: current state of the art and emerging therapeutic approaches.

Medical oncology (Northwood, London, England)·2022
Same author

Radium-223 in the Treatment of Metastatic Castrate-Resistant Prostate Cancer.

Irish medical journal·2022
Same author

Immune Checkpoint Inhibitors and Palliative Care at the End of Life: An Irish Multicentre Retrospective Study.

Journal of palliative care·2022
Same author

Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.

European journal of cancer (Oxford, England : 1990)·2021

Related Experiment Video

Updated: Apr 15, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

Enzalutamide: Development from bench to bedside.

R M Bambury1, H I Scher1

  • 1Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Urologic Oncology
|March 24, 2015
PubMed
Summary
This summary is machine-generated.

Enzalutamide offers improved efficacy over older drugs for prostate cancer by targeting androgen receptor (AR) signaling. Research continues on resistance mechanisms and broader applications of this AR antagonist.

Keywords:
AR targeted therapiesEnzalutamideMDV3100Prostate cancercastration resistant prostate cancer

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.4K

Related Experiment Videos

Last Updated: Apr 15, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

14.0K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment
08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.4K

Area of Science:

  • Oncology
  • Pharmacology
  • Urology

Background:

  • Prostate cancer growth relies on androgen receptor (AR) signaling.
  • Androgen deprivation therapy is a long-standing treatment for metastatic prostate cancer.
  • First-generation AR antagonists like bicalutamide have limitations, including partial agonist activity in certain cases.

Purpose of the Study:

  • To detail the preclinical discovery and clinical development of enzalutamide.
  • To highlight enzalutamide's approval as a standard therapy for castration-resistant prostate cancer.
  • To discuss ongoing research into resistance mechanisms and new applications for enzalutamide.

Main Methods:

  • Preclinical studies evaluating AR antagonist efficacy.
  • Clinical trials assessing safety and effectiveness in prostate cancer patients.
  • Mechanistic studies investigating resistance pathways to AR-targeted therapies.

Main Results:

  • Enzalutamide demonstrates superior efficacy compared to first-generation AR antagonists.
  • Enzalutamide is approved for castration-resistant prostate cancer treatment.
  • Understanding resistance mechanisms is crucial for optimizing AR-targeted therapy.

Conclusions:

  • Enzalutamide represents a significant advancement in prostate cancer treatment by effectively inhibiting AR signaling.
  • Further research is needed to overcome resistance and expand the use of enzalutamide in various prostate cancer settings and other malignancies.